Effectiveness of Biological Agents in the Treatment of Pediatric Patients with Crohn’s Disease and Anal Fistulae
Open Access
- 21 January 2021
- journal article
- research article
- Published by S. Karger AG in Digestion
- Vol. 102 (5), 783-788
- https://doi.org/10.1159/000512900
Abstract
Introduction: Anal fistulae have a significant impact on the quality of life of patients with Crohn’s disease (CD). In this cross-sectional study, we aimed to determine whether biological agents were effective in treating anal fistulae in patients with CD. Methods: Fifty-three patients diagnosed with CD were retrospectively enrolled. Their data regarding symptoms, treatments, and disease progression from January 2007 to December 2016 were reviewed from the medical records. Fifteen (28%) patients with CD were complicated by anal fistulae. Results: The male-to-female ratio was 13:2, and the mean age at onset was 11 years and 6 months. Among the 15 patients, 14 (93%) had anal fistulae as an initial symptom. Almost all patients were treated by providing elemental diet, 5-aminosalicylic acid, and steroids as induction therapy. Biological agents were used in 8 patients (53.3%), and fistula closure was confirmed in all of them. Among the 7 patients not treated with biological agents, 1 (14.3%) had a recurrent anal fistula, while another had incomplete fistula closure. Regarding surgical management, 2 patients were treated using the seton method, and no patients required a colostomy. Conclusion: Treatment with biological agents is highly effective concerning the closure of anal fistulae in patients with CD, and reducing pain may improve their quality of life.Keywords
This publication has 21 references indexed in Scilit:
- Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapyEuropean Journal of Gastroenterology & Hepatology, 2011
- Recognition and treatment of genitourinary complications in paediatric Crohn’s disease using InfliximabActa Paediatrica, 2010
- Inflammatory Bowel DiseaseThe New England Journal of Medicine, 2009
- Infliximab Therapy in Children With Concurrent Perianal Crohn Disease: Observations From REACHJournal of Pediatric Gastroenterology and Nutrition, 2009
- Diagnosis and management of fistulizing Crohn's diseaseNature Clinical Practice Gastroenterology & Hepatology, 2009
- Perianal Fistulizing Crohn’s Disease: A Call to ActionClinical Gastroenterology and Hepatology, 2008
- Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in ChildrenGastroenterology, 2007
- Infliximab in Pediatric Crohn Disease Patients With Enterovesicular FistulasJournal of Pediatric Gastroenterology and Nutrition, 2007
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseThe New England Journal of Medicine, 1999
- Tumour-necrosis-factor antibody treatment in Crohn's diseaseThe Lancet, 1993